ACCC is seeking to fill open positions on its Governmental Affairs Committee. The Committee monitors federal and state legislation and advises the Board of Trustees and the membership on matters that will impact reimbursement and access in community cancer care. The Committee recommends ways that ACCC can be most effective in influencing the executive and legislative branches of federal and state governments consistent with ACCC’s core purpose and strategic objectives. In addition to policymakers in Congress and the Centers for Medicare & Medicaid Services, the Committee works to establish relationships and maintain communication with federal agencies, independent organizations, and fellow stakeholders to advocate for the needs of the nation’s cancer patients as perceived by the leadership of community cancer programs.

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.
